142 related articles for article (PubMed ID: 34646761)
1. Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy.
Kerr MWA; Magalhães-Gama F; Ibiapina HNS; Hanna FSA; Xabregas LA; Alves EB; Pimentel JPD; Carvalho MPSS; Tarragô AM; Teixeira-Carvalho A; Martins-Filho OA; da Costa AG; Malheiro A
Front Oncol; 2021; 11():696032. PubMed ID: 34646761
[TBL] [Abstract][Full Text] [Related]
2. Systemic immunological profile of children with B-cell acute lymphoblastic leukemia: performance of cell populations and soluble mediators as serum biomarkers.
Carvalho MPSS; Magalhães-Gama F; Loiola BP; Neves JCF; Araújo ND; Silva FS; Catão CLS; Alves EB; Pimentel JPD; Barbosa MNS; Fraiji NA; Teixeira-Carvalho A; Martins-Filho OA; Costa AG; Malheiro A
Front Oncol; 2023; 13():1290505. PubMed ID: 38107068
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of Chemokines and Cytokines in the Bone Marrow Microenvironment of Children with B-Cell Acute Lymphoblastic Leukemia.
Magalhães-Gama F; Kerr MWA; de Araújo ND; Ibiapina HNS; Neves JCF; Hanna FSA; Xabregas LA; Carvalho MPSS; Alves EB; Tarragô AM; Martins-Filho OA; Teixeira-Carvalho A; Malheiro A; da Costa AG
J Oncol; 2021; 2021():5530650. PubMed ID: 34335758
[TBL] [Abstract][Full Text] [Related]
4. Mediators Go Together: High Production of CXCL9, CXCL10, IFN-γ, and TNF-α in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
Neco HVPDC; Teixeira VGDS; da Trindade ACL; Magalhães PMR; de Lorena VMB; Castellano LRC; de Souza JR; Vasconcelos LR; de Moura PMMF; de Morais CNL
AIDS Res Hum Retroviruses; 2017 Nov; 33(11):1134-1139. PubMed ID: 28648091
[TBL] [Abstract][Full Text] [Related]
5. Cytokines and soluble HLA-G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T-cell acute lymphoblastic leukemia.
Almeida RDS; Ramos AML; Luna CF; Pedrosa F; Donadi EA; Lucena-Silva N
Cytokine; 2018 Feb; 102():94-101. PubMed ID: 28802664
[TBL] [Abstract][Full Text] [Related]
6. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
[TBL] [Abstract][Full Text] [Related]
7. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
8. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
9. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
10. Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
DiGiuseppe JA; Tadmor MD; Pe'er D
Cytometry B Clin Cytom; 2015; 88(5):294-304. PubMed ID: 25974871
[TBL] [Abstract][Full Text] [Related]
11. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic significance of minimal residual disease detection after first induction treatment in adult acute lymphoblastic leukemia patients treated with autologous stem cell transplantation].
Huang ZF; Xu J; Fu MW; Wang TY; Hao M; Liu W; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):105-110. PubMed ID: 30831624
[No Abstract] [Full Text] [Related]
13. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
14. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
15. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
16. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.
Orgel E; Tucci J; Alhushki W; Malvar J; Sposto R; Fu CH; Freyer DR; Abdel-Azim H; Mittelman SD
Blood; 2014 Dec; 124(26):3932-8. PubMed ID: 25349177
[TBL] [Abstract][Full Text] [Related]
18. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
Chang L; Zhang G; Shi H; Ye L; Jiang YM
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
[TBL] [Abstract][Full Text] [Related]
20. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
Blood; 2002 Oct; 100(7):2399-402. PubMed ID: 12239148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
